# Artificial Intelligence in health(care) Guidance for assessing, monitoring and auditing

## **Carl Moons**

Prof. Clinical Epidemiology, Julius Center, UMC Utrecht Directeur Health Innovation Netherlands (HI-NL) Figure head 'AI for Health', UMC Utrecht/Utrecht University Project leader Government initiative 'Quality of AI in Health'




# Health(care) challenges





## MedTech






## And then ... it became 2020





## And then ... there was suddenly AI to battle COVID-19





## **COVID-19 decision algorithms**

In <15 mths over 1200 COVID-19 algorithms - >70% Al based

RESEARCH







# Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal

Laure Wynants, <sup>1,2</sup> Ben Van Calster, <sup>2,3</sup> Gary S Collins, <sup>4,5</sup> Richard D Riley, <sup>6</sup> Georg Heinze, <sup>7</sup> Ewoud Schuit, <sup>8,9</sup> Elena Albu, <sup>2</sup> Banafsheh Arshi, <sup>1</sup> Vanesa Bellou, <sup>10</sup> Marc M J Bonten, <sup>8,11</sup> Darren L Dahly, <sup>12,13</sup> Johanna A Damen, <sup>8,9</sup> Thomas P A Debray, <sup>8,14</sup> Valentijn M T de Jong, <sup>8,9</sup> Maarten De Vos, <sup>2,15</sup> Paula Dhiman, <sup>4,5</sup> Joie Ensor, <sup>6</sup> Shan Gao, <sup>2</sup> Maria C Haller, <sup>7,16</sup> Michael O Harhay, <sup>17,18</sup> Liesbet Henckaerts, <sup>19,20</sup> Pauline Heus, <sup>8,9</sup> Jeroen Hoogland, <sup>8</sup> Mohammed Hudda, <sup>21</sup> Kevin Jenniskens, <sup>8,9</sup> Michael Kammer, <sup>7,22</sup> Nina Kreuzberger, <sup>23</sup> Anna Lohmann, <sup>24</sup> Brooke Levis, <sup>6</sup> Kim Luijken, <sup>24</sup> Jie Ma, <sup>5</sup> Glen P Martin, <sup>25</sup> David J McLernon, <sup>26</sup> Constanza L Andaur Navarro, <sup>8,9</sup> Johannes B Reitsma, <sup>8,9</sup> Jamie C Sergeant, <sup>27,28</sup> Chunhu Shi, <sup>29</sup> Nicole Skoetz, <sup>22</sup> Luc J M Smits, <sup>1</sup> Kym I E Snell, <sup>6</sup> Matthew Sperrin, <sup>30</sup> René Spijker, <sup>8,9,31</sup> Ewout W Steyerberg, <sup>3</sup> Toshihiko Takada, <sup>8,32</sup> Ioanna Tzoulaki, <sup>10,33</sup> Sander M J van Kuijk, <sup>34</sup> Bas C T van Bussel, <sup>1,35</sup> Iwan C C van der Horst, <sup>35</sup> Kelly Reeve, <sup>36</sup> Florien S van Royen, <sup>8</sup> Jan Y Verbakel, <sup>37,38</sup> Christine Wallisch, <sup>7,39,40</sup> Jack Wilkinson, <sup>24</sup> Robert Wolff, <sup>41</sup> Lotty Hooft, <sup>8,9</sup> Karel G M Moons, <sup>8,9</sup> Maarten van Smeden <sup>8</sup>

For numbered affiliations see end of the article

Correspondence to: L Wynants laure.wynants@ maastrichtuniversity.nl (ORCID 0000-0002-3037-122X)

Additional material is published online only. To view please visit

#### Abstract

#### **OBJECTIVE**

To review and appraise the validity and usefulness of published and preprint reports of prediction models for prognosis of patients with covid-19, and for detecting people in the general population at increased risk of covid-19 infection or being admitted

#### DATA EXTRACTION

At least two authors independently extracted data using the CHARMS (critical appraisal and data extraction for systematic reviews of prediction modelling studies) checklist; risk of bias was assessed using PROBAST (prediction model risk of bias assessment tool).

RESULTS

## **COVID-19 left – Al stayed**



HOT TOPICS

#### **Machine Learning Will Change Medicine**

Michael Forsting

Essen University Hospital, University of Essen-Duisburg, Essen, Germany

# Artificial Intelligence in Health Care

The Hope, the Hype, the Promise, the Peril

### Doctors about to be replaced by hospital AI systems offering better diagnosis and less arrogance

09/12/2017 / By Thoanna Pohinson












Framingham, Massachusetts-based market intelligence provider IDC Health Insights, in its recently published report on artificial intelligence and cognitive computing adoption in the AssaiPacific (Etcholing Japan), stated the best possible healthcare solutions that hospitals and health insurance companies all around the AssaiPacific countries should adopt.



REFLECTIONS ON HEALTHCARE LEADERSHIP ETHICS

#### Healthcare uses of artificial intelligence: Challenges and opportunities for growth

Eric Racine, PhD<sup>1,2,3,4</sup>; Wren Boehlen, BSc<sup>1</sup>; and Matthew Sample, PhD<sup>1,2</sup>



Healthcare Management Forum 2019, Vol. 32(5) 272-275 ■ 2019 The Canadian College of Health Leaders. All rights reserved. Article reuse guidelines: sagepub.com/journals-permissions DOE: 10.1177/08/04/70419843831 journals.sagepub.com/homelhmf


(\$)SAGE



e I d n

m

## Al will be everywhere – no mayfly or one trick pony





## Short Intermezzo - Al Quiz



### Can you guess the publication year?

- 1. History of Artificial Intelligence
- 1. Artificial Intelligence: The Time is Now.
- 1. Artificial intelligence techniques for diagnostic reasoning in medicine
- 1. The evaluation of artificial intelligence systems in medicine.







## Quiz


Can you guess the publication year?

- History of Artificial Intelligence (McCorduck et al., 1977)
- 1. Artificial Intelligence: The Time is Now. (R.L. Dilworth, 1988)
- 1. Artificial intelligence techniques for diagnostic reasoning in medicine (R.S., Patil, 1988)
- 1. The evaluation of artificial intelligence systems in medicine. (P.L. Miller; 1986)










### What is AI?

Human intelligence artificialized (computerised)

- Image/seeing to text v.v.
- Sound/hearing to text v.v.
- Detecting patterns in data/images/sounds
- Multiple data sources/types combined+translated to, e.g., a probability → forecasting or detecting (e.g. weather, traffic, stocks, health)
- Etc. our brain is great!





## 2 main types of AI in health(care) domain

- 1. To support in the decision making of health providers, patients and citizens
- 2. To support healthcare processes/efficiency/workload reduction





# 1. Al to support decision making → health providers, patients, citizens

Detection - diagnoses / screening







Prognosis – predicting future health outcomes, treatment effects



- Monitoring disease progress, therapy response, remote
- Lifestyle/exercise planning





- Therapy conduct









#### **OPINION**

updates

published: 26 January 2022 doi: 10.3389/fdgth.2022.833912


- 10.000
  - Very

## - Al is goir Artificial Intelligence and Statistics: **Just the Old Wine in New Wineskins?**

Livia Faes 1,2\*, Dawn A. Sim 1,3,4, Maarten van Smeden 5, Ulrike Held 6, Patrick M. Bossuyt 7 and Lucas M. Bachmann<sup>2</sup>


<sup>1</sup> Medical Retina Department, Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom, <sup>2</sup> Medignition Inc., Research Consultants, Zurich, Switzerland, <sup>3</sup> Health Data Research UK, London, United Kingdom, <sup>4</sup> National Institute for Health Research (NIHR) Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital National Health Service (NHS) Foundation Trust and University College London (UCL) Institute of Ophthalmology, London, United Kingdom, 5 Julius Center for Health Science and Primary Care, University Medical Center Utrecht, University of Utrecht, Utrecht, Netherlands, <sup>6</sup> Department of Biostatistics, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland, <sup>7</sup> Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam Public Health Research Institute, Amsterdam University Medical Centers, Amsterdam, Netherlands

Keywords: artificial intelligence (AI), machine learning (ML), statistics, methodology, reporting guideline



A new predi is developed

...every 1.5



alth(care)

## Leaky pipeline prediction algorithms in health(care)

Not fit for purpose	No validation	No implementation	Not adopted
Developed on wrong patient population	Lack of data or incentive to pursue validation studies	No impact on decision making or patient (health) outcomes	Prediction (perceived as) not useful
Expensive or non-available predictors	Incompletely reported prediction model	No software developed to implement and use the model	Predictions not trusted
Time intensive to use model	Poorly developed or overfitted model	Requirements for adherence to (medical device) regulations	Model not transparent enough, or no tools available to enhance its use in practice
Outcome measured unreliably	Proprietary model code	Cost(-effectiveness) of use proprietary model	Model (perceived as) outdated

# 2. Al to reduce workload and administrative burden – generative Al (since end 2022 – the game changer?)

- Automated discharge letters
- Patient summaries
- Consult to text into EPD
- No show-up scheduled poli-clinic visits
- Chatbot











03 May 2023: Godfather Al leaves Go

Al-pionier Geoffrey Hinton leaves experts that worry about the introd accuracy of Al





www.nature.com

AI in healthcare

5-4

Elementary school teachers picket against use of calculators in grade school

The teachers feel if students use calculators too early, they won't learn math concepts

# Math teachers protest against calculator use

By JILL LAWRENCE

"My older kids don't pay any strate, attention to an answer being absurd. shy."

strate," he said. "Teachers are

lance!

21

## Why so concerned w.r.t. AI in health(care)?

- Al is already everywhere around us anyway
  - Health domain is not Netflix, Booking, Google maps, Weather forecasting
- Health domain keeps human (provider, patient, citizen) in the loop -> but for how long?
  - On other hand: realisation that AI might also be better suited for various medical tasks (predict and detect better; not tired; no off-day, etc.)
- Other parties entered the health field Google amazon Microsoft & OpenA
- Al is not a drug
  - Drug guidance set in stone + transparent + instructions for use
  - Everything is known at moment of market access
  - Drugs from provider→ drugstore→ patient/citizen; AI from company directly to citizen
  - Al similar but different life-cycle than drugs





### Evaluation/auditing criteria needed per phase

From data, to development, to evaluation, software, impact, implementation, Monitoring/updating



#### Phase 0

Project idea and preparation



#### Phase 1

Collection and management of the Data



#### Phase 2

Development of the AI



#### Phase 3

Validation of the AI



#### Phase 4

Development of the required software



#### Phase 5

Impact assessment
of the AI
in combination with the
software



#### Phase 6

Implementation of AI+software in daily practice, including monitoring (PMS)



### 2 valleys of death



Healthcare problem

prototype

Technical feasibility

Proof of concept CE

Validation, Impact & Costeffectiveness

Implementation + Adoption


Upscaling Monitoring





# MedTech/AI – bumpy road





# We need guidance for 'AI in Health(care)' (before we upscale it to everyone)

Guidance for assessment, monitoring, auditing on:

- Explainability and Transparency
- Trustworthiness (validity, Fairness, risks of bias, safety)



# Transparent & Explainable AI in Health (both AI types) TRIPOD+AI www.tripod-statement.org



www.tripod-statement.org Cite this as: BMJ 2024;385:e078378

# TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods

Gary S Collins, <sup>1</sup> Karel G M Moons, <sup>2</sup> Paula Dhiman, <sup>1</sup> Richard D Riley, <sup>3,4</sup> Andrew L Beam, <sup>5</sup> Ben Van Calster, <sup>6,7</sup> Marzyeh Ghassemi, <sup>8</sup> Xiaoxuan Liu, <sup>9,10</sup> Johannes B Reitsma, <sup>2</sup> Maarten van Smeden, <sup>2</sup> Anne-Laure Boulesteix, <sup>11</sup> Jennifer Catherine Camaradou, <sup>12,13</sup> Leo Anthony Celi, <sup>14,15,16</sup> Spiros Denaxas, <sup>17,18</sup> Alastair K Denniston, <sup>4,9</sup> Ben Glocker, <sup>19</sup> Robert M Golub, <sup>20</sup> Hugh Harvey, <sup>21</sup> Georg Heinze, <sup>22</sup> Michael M Hoffman, <sup>23,24,25,26</sup> André Pascal Kengne, <sup>27</sup> Emily Lam, <sup>12</sup> Naomi Lee, <sup>28</sup> Elizabeth W Loder, <sup>29,30</sup> Lena Maier-Hein, <sup>31</sup> Bilal A Mateen, <sup>17,32,33</sup> Melissa D McCradden, <sup>34,35</sup> Lauren Oakden-Rayner, <sup>36</sup> Johan Ordish, <sup>37</sup> Richard Parnell, <sup>12</sup> Sherri Rose, <sup>36</sup> Karandeep Singh, <sup>38</sup> Laure Wynants, <sup>40</sup> Patricia Logullo<sup>1</sup>







Nature Medicine 2024 www.tripod-statement.org

Follow this prepr

## The TRIPOD-LLM Statement: A Targeted Guideline For Reporting Large Language Models Use

Diack Gallifant, Majid Afshar, Saleem Ameen, Yindalon Aphinyanaphongs, Shan Chen, Giovanni Cacciamani, Dina Demner-Fushman, Dmitriy Dligach, Roxana Daneshjou, Chrystinne Fernandes, Lasse Hyldig Hansen, Adam Landman, Lisa Lehmann, Liam G. McCoy, Timothy Miller, Amy Moreno, Nikolaj Munch, David Restrepo, Guergana Savova, Renato Umeton, Judy Wawira Gichoya, Gary S. Collins, Karel G. M. Moons, Leo A. Celi, Danielle S. Bitterman

doi: https://doi.org/10.1101/2024.07.24.24310930

# Trustworthy, FAIR & unbiased AI in Health PROBAST+AI; www.probast.org

BMJ Open Protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction model studies based on artificial intelligence

```
Gary S Collins (1), 1,2 Paula Dhiman (1), 1,2 Constanza L Andaur Navarro (1), 3

Jie Ma (1), 1 Lotty Hooft, 3,4 Johannes B Reitsma, 3 Patricia Logullo (1), 1,2


Andrew L Beam (1), 5,6 Lily Peng, 7 Ben Van Calster (1), 8,9,10

Maarten van Smeden (1), 3 Richard D Riley (1), 11 Karel GM Moons<sup>3,4</sup>
```

**Lancet Digit Health.** 2024 Jul;6(7):e441-e443. doi: 10.1016/S2589-7500(24)00111-0.


# From text to treatment: the crucial role of validation for generative large language models in health care

Anne de Hond <sup>1</sup>, Tuur Leeuwenberg <sup>2</sup>, Richard Bartels <sup>3</sup>, Marieke van Buchem <sup>4</sup>, Ilse Kant <sup>5</sup>, Karel Gm Moons <sup>2</sup>, Maarten van Smeden <sup>2</sup>



## Guideline for Al in healthcare https://guideline-ai-healthcare.com

#### Because AI is not a drug (MDR/IVDR)







https://guideline-ai-healthcare.com

https://leidraad-Al.nl



## Al guidance/auditing <a href="https://guideline-ai-healthcare.com">https://guideline-ai-healthcare.com</a>

From data, to development, to evaluation, software, impact & implementation, Monitoring



#### Phase 0

Project idea and preparation



#### Phase 1

Collection and management of the Data



#### Phase 2

Development of the AI



#### Phase 3

Validation of the AI



#### Phase 4

Development of the required software



#### Phase 5

Impact assessment of the AI in combination with the software



#### Phase 6

Implementation of AI+software in daily practice, including monitoring (PMS)



### **Guidance per phase**

- Per phase explicit criteria and hands-on guidance based on current state-of-science
- What the field considers good conduct in development, testing, implementation of AI, before widescale use in our patients/clients/citizens
  - Requirements vs. recommendations per phase
  - Guideline beyond the MDR/IVDR



### c h e

### e A I

# Guidance and E-learning tailored to targeted **groups** <a href="https://guideline-ai-healthcare.com">https://guideline-ai-healthcare.com</a>







**Developing AI** 



**Assessing AI** 



Society

Healthcare
provider
Professional
Scientific
Medical
associations
Education/training
IT suppliers
Patient / Citizen

Validator Responsible developer Researcher Data manager Data supplier (Internal) supervisor
Notified body Peer
reviewer Privacy
officer
Competent Authority
Auditor
Insurer (DiGiZo)

Patient(s)(associations)
Interest parties
Politcy parties
Interested citizen
HINL



Similar Guideline for Generative Al underway

- 1. Development not necessarily on large, inclusive datasets
  - Such data sets do not exist, not needed

- Compare:





Richer data not always better models

**OPINION** 

### A.I. Could Worsen Health Disparities

In a health system riddled with inequity, we risk making dangerous biases automated and invisible.

Jan. 31, 2019

- 2. Validation most important Test, Test, Test before use
  - use AI Guideline to determine what is (un)known at moment of assessing/auditing
- 3. Often heard: Al goes fast, can we keep up? YES: our valuations/guidance do 'not' change.
- 4. Not AI ready? Yes we are! Algorithms not new in health(care). Gen-AI is.
- 5. Al replaces us humans? No. Compare Netflix, Booking, Maps.







The gateway to European market for medtech, biotech

To bridge the 2 valleys of death


www.healthinnovation.nl



# Providing a clear and shorter path for innovators



The way to market is a bumpy ride – with many stakeholders involved sequentially.



HI-NL brings all relevant stakeholders together early on, providing a clear path and tailored guidance endorsed by all stakeholders.



### www.healthinnovation.nl





## **Take aways**

- 1. Al in health domain different from films, hotels, road directions
- 2. Richer data not necessarily required for more fair or better Al
  - → it is all about testing, testing and testing before use
  - → transparency on what data developed & tested → AI leaflet needed
- 3. At is not a drug  $\rightarrow$  unclear how developed, tested, on which data, no instructions for use
- 4. Trustworthiness guidance for AI in healthcare, needs to be applied NOW!
  - Human remains in the loop but for how long?
  - And ....Al soon directly sold from companies to citizens/patients



## **Take aways**

- 5. Monitoring/auditing notably needed for AI that directly goes from company  $\rightarrow$  citizens/patients
  - no healthcare provider in-between anymore
- 6. Drugs do not change after market access/implementation → AI does (self-adjusting)
  - Extra reason for good monitoring and auditing
  - Guidance for AI-PMS is thus different from Drug-PMS
- 7. Much monitoring and auditing guidance exists see above.
  - Use it wisely and use it NOW!
  - We seem to act too slow? Not wait for 'tax-fraud' / 'wrong criminal' case.



### www.healthinnovation.nl

# Thank you!



https://guideline-ai-healthcare.com

Al quality tool



TRIPOD+AI: www.tripod-statement.org



PROBAST+AI: www.probast.org

